Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05519293 |
Recruitment Status :
Recruiting
First Posted : August 29, 2022
Last Update Posted : April 11, 2024
|
Sponsor:
RedCloud Bio
Collaborator:
Parexel
Information provided by (Responsible Party):
RedCloud Bio
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Recruiting |
---|---|
Estimated Primary Completion Date : | February 28, 2025 |
Estimated Study Completion Date : | February 28, 2025 |